New advances in leukaemia immunotherapy by the use of Chimeric Artificial Antigen Receptors (CARs): State of the art and perspectives for the near future

Italian Journal of Pediatrics

Volumn 37, Issue 1, 2011, Pages

  Biagi, Ettore ^a   Marin, Virna ^a   Attianese, Greta Maria Paola Giordano ^a   Pizzitola, Irene ^a   Tettamanti, Sarah ^a   Cribioli, Elisabetta ^a   Biondi, Andrea ^a  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

cell therapy; chimeric artificial receptors; gene therapy; Leukaemia immunotherapy

Indexed keywords

CD19 ANTIGEN; CD28 ANTIGEN; CD33 ANTIGEN; CHIMERIC ARTIFICIAL ANTIGEN RECEPTOR; CYCLOPHOSPHAMIDE; DIASIALOGANGLIOSIDE G; FLUDARABINE; GANGLIOSIDE; LUMILIXIMAB; LYMPHOCYTE ANTIGEN RECEPTOR; MONOCLONAL ANTIBODY; OKT 3; RITUXIMAB; UNCLASSIFIED DRUG; HYBRID PROTEIN; PEPTIDE FRAGMENT;

ACUTE GRANULOCYTIC LEUKEMIA; CANCER IMMUNOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; CYTOTOXIC T LYMPHOCYTE; EPSTEIN BARR VIRUS; HEMATOLOGY; HUMAN; LEUKEMIA; LYMPH NODE; LYMPHATIC LEUKEMIA; LYMPHOCYTE COUNT; NEUROBLASTOMA; NONHUMAN; PROTEIN EXPRESSION; REVIEW; SIDE EFFECT; ADOPTIVE IMMUNOTHERAPY; GENETICS; IMMUNOLOGY; METHODOLOGY; MYELOID LEUKEMIA; SIGNAL TRANSDUCTION;

HUMANS; IMMUNOTHERAPY, ADOPTIVE; LEUKEMIA; LEUKEMIA, LYMPHOID; LEUKEMIA, MYELOID; PEPTIDE FRAGMENTS; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION;

EID: 84857174465     PISSN: 17208424     EISSN: 18247288     Source Type: Journal    
DOI: 10.1186/1824-7288-37-46     Document Type: Review

References (40)

1. Genetic modification of T lymphocytes for adoptive immunotherapy. Rossig C, Brenner MK, Mol Ther 2004 10 5 18 Review 10.1016/j.ymthe.2004.04.014 15233937 (Pubitemid 38878144)
2. Current status of genetic modification of T cells for cancer treatment. Dotti G, Heslop HE, Cytotherapy 2005 7 262 272 Review 10.1080/14653240510027217 16081353 (Pubitemid 41051369)
3. Chimeric T-cell receptors: new challenges for targeted immunotherapy in hematologic malignancies. Biagi E, Marin V, Giordano Attianese GM, Dander E, D'Amico G, Biondi A, Haematologica 2007 92 381 388 Review 10.3324/haematol.10873 17339188 (Pubitemid 350143548)
4. CARs on track in the clinic. Kohn DB, Dotti G, Brentjens R, Savoldo B, Jensen M, Cooper LJ, June CH, Rosenberg S, Sadelain M, Heslop HE, Mol Ther 2011 19 432 438 10.1038/mt.2011.1 21358705
5. Chimeric T-cell receptors for the targeting of cancer cells. Rössig C, Brenner MK, Acta Haematol 2003 110 154 159 Review 10.1159/000072465 14583676 (Pubitemid 37340194)
6. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Pule MA, Savoldo B, Myers GD, Rossig C, Russell HV, Dotti G, Huls MH, Liu E, Gee AP, Mei Z, Yvon E, Weiss HL, Liu H, Rooney CM, Heslop HE, Brenner MK, Nat Med 2008 14 1264 1270 10.1038/nm.1882 18978797
7. Supernatural T cells: genetic modification of T cells for cancer therapy. Kershaw MH, Teng MW, Smyth MJ, Darcy PK, Nat Rev Immunol 2005 5 928 940 10.1038/nri1729 16322746 (Pubitemid 41746762)
8. Johnson Assembly PCR oligo maker: a tool for designing oligodeoxynuleotides for constructing long DNA molecules for RNA production. Rydzanicz Roman, Sharon Zhao X, Philip E, Nucleic Acids Research 2005 33 Web Server 521 525
9. Characterization of in vitro migratory properties of anti-CD19 chimeric receptor-redirected CIK cells for their potential use in B-ALL immunotherapy. Marin V, Dander E, Biagi E, Introna M, Fazio G, Biondi A, D'Amico G, Exp Hematol 2006 34 1219 1229 16939815
10. Enhancement of the anti-leukemic activity of cytokine induced killer cells with an anti-CD19 chimeric receptor delivering a 4-1BB-zeta activating signal. Marin V, Kakuda H, Dander E, Imai C, Campana D, Biondi A, D'Amico G, Exp Hematol 2007 35 1388 1397 10.1016/j.exphem.2007.05.018 17656004 (Pubitemid 47302588)
11. Cytotoxic T cells transduced with chimeric anti-CD19 receptors prevent engraftment of primary lymphoblastic leukemia in vivo. Landmeier S, Altvater B, Pscherer S, Meltzer J, Sebire N, Pule M, Vera J, Hotfilder M, Juergens H, Vormoor J, Rossig C, Leukemia 2010 24 1080 1084 10.1038/leu.2010.38 20220773
12. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. Savoldo B, Ramos CA, Liu E, Mims MP, Keating MJ, Carrum G, Kamble RT, Bollard CM, Gee AP, Mei Z, Liu H, Grilley B, Rooney CM, Heslop HE, Brenner MK, Dotti G, J Clin Invest 2011 121 1822 1826 10.1172/JCI46110 21540550
13. Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. Zhao Y, Moon E, Carpenito C, Paulos CM, Liu X, Brennan AL, Chew A, Carroll RG, Scholler J, Levine BL, Albelda SM, June CH, Cancer Res 2010 70 9053 9061 10.1158/0008-5472.CAN-10-2880 20926399
14. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Kochenderfer JN, Wilson WH, Janik JE, Dudley ME, Stetler-Stevenson M, Feldman SA, Maric I, Raffeld M, Nathan DA, Lanier BJ, Morgan RA, Rosenberg SA, Blood 2010 116 4099 4102 10.1182/blood-2010-04-281931 20668228
15. The hyperactive Sleeping Beauty transposase SB100X improves the genetic modification of T cells to express a chimeric antigen receptor. Jin Z, Maiti S, Huls H, Singh H, Olivares S, Mátés L, Izsvák Z, Ivics Z, Lee DA, Champlin RE, Cooper LJ, Gene Ther 2011
16. The role of gemtuzumab ozogamicin in acute leukaemia therapy. Tsimberidou AM, Giles FJ, Estey E, O'Brien S, Keating MJ, Kantarjian HM, Br J Haematol 2006 132 398 409 Review 16412015 (Pubitemid 43381615)
17. Prospective trial of high-dose chemotherapy followed by infusions of peripheral blood stem cells and dose-escalated donor lymphocytes for relapsed leukemia after allogeneic stem cell transplantation. Takami A, Okumura H, Yamazaki H, Kami M, Kim SW, Asakura H, Endo T, Nishio M, Minauchi K, Kumano K, Sugimori N, Mori S, Takemoto Y, Shimadoi S, Ozaki J, Takaue Y, Nakao S, Int J Hematol 2005 82 449 455 10.1532/IJH97.05086 16533751 (Pubitemid 46638697)
18. A novel MHC-associated proteinase 3 peptide isolated from primary chronic myeloid leukaemia cells further supports the significance of this antigen for the immunotherapy of myeloid leukaemias. Knights AJ, Weinzierl AO, Flad T, Guinn BA, Mueller L, Mufti GJ, Stevanovic S, Pawelec G, Leukemia 2006 20 1067 1072 10.1038/sj.leu.2404234 16628186 (Pubitemid 43797299)
19. Cytokine-induced killer cells for cell therapy of acute myeloid leukemia: improvement of their immune activity by expression of CD33-specific chimeric receptors. Marin V, Pizzitola I, Agostoni V, Attianese GM, Finney H, Lawson A, Pule M, Rousseau R, Biondi A, Biagi E, Haematologica 2010 95 2144 2152 10.3324/haematol.2010.026310 20713459
20. Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: a phase I study. Introna M, Borleri G, Conti E, Franceschetti M, Barbui AM, Broady R, Dander E, Gaipa G, D'Amico G, Biagi E, Parma M, Pogliani EM, Spinelli O, Baronciani D, Grassi A, Golay J, Barbui T, Biondi A, Rambaldi A, Haematologica 2007 92 952 959 10.3324/haematol.11132 17606446 (Pubitemid 350144242)
21. B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced B lymphocytes. Damle RN, Ghiotto F, Valetto A, Albesiano E, Fais F, Yan XJ, Sison CP, Allen SL, Kolitz J, Schulman P, Vinciguerra VP, Budde P, Frey J, Rai KR, Ferrarini M, Chiorazzi N, Blood 2002 99 4087 4093 10.1182/blood.V99.11.4087 12010811 (Pubitemid 35332051)
22. Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. Byrd JC, Kipps TJ, Flinn IW, Castro J, Lin TS, Wierda W, Heerema N, Woodworth J, Hughes S, Tangri S, Harris S, Wynne D, Molina A, Leigh B, O'Brien S, Blood 2010 115 489 495 10.1182/blood-2009-08-237727 19843887
23. In vitro and in vivo model of a novel immunotherapy approach for chronic lymphocytic leukemia by anti-CD23 chimeric antigen receptor. Giordano Attianese GMP, Marin V, Hoyos V, Savoldo B, Pizzitola I, Tettamanti S, Agostoni V, Parma M, Ponzoni M, Bertilaccio MT, Ghia P, Biondi A, Dotti G, Biagi E, Blood 2011 117 4736 4745 10.1182/blood-2010-10-311845 21406718
24. A novel Rag2-/-gammac-/ - xenograft model of human CLL. Bertilaccio MT, Scielzo C, Simonetti G, Ponzoni M, Apollonio B, Fazi C, Scarf L, Rocchi M, Muzio M, Caligaris-Cappio F, Ghia P, Blood 2010 115 1605 1609 10.1182/blood-2009-05- 223586 20018917
25. A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Pulè MA, Straathof KC, Dotti G, Heslop HE, Rooney CM, Brenner MK, Mol Ther 2005 12 933 941 10.1016/j.ymthe.2005.04.016 15979412 (Pubitemid 41614489)
26. PD-1 and PD-1 ligands: from discovery to clinical application. Okazaki T, Honjo T, Int Immunol 2007 19 813 824 Review 10.1093/intimm/dxm057 17606980 (Pubitemid 47241890)
27. Cytokine-induced NK-like T cells: from bench to bedside. Linn YC, Hui KM, J Biomed Biotechnol 2010 2010 435745 Epub 2010 Mar 30. Review 20368995
28. Human gammadelta T cells: a nonredundant system in the immune-surveillance against cancer. Ferrarini M, Ferrero E, Dagna L, Poggi A, Zocchi MR, Trends Immunol 2002 23 14 18 Review 10.1016/S1471-4906(01)02110-X 11801449 (Pubitemid 34098956)
29. Phosphostim-activated gamma delta T cells kill autologous metastatic renal cell carcinoma. Viey E, Fromont G, Escudier B, Morel Y, Da Rocha S, Chouaib S, Caignard A, J Immunol 2005 174 1338 1347 15661891
30. Human gammadelta T cells as mediators of chimaeric-receptor redirected anti-tumour immunity. Rischer M, Pscherer S, Duwe S, Vormoor J, Jürgens H, Rossig C, Br J Haematol 2004 126 583 592 10.1111/j.1365-2141.2004.05077.x 15287953 (Pubitemid 39093102)
31. In Vitro Comparison of Three Different Chimeric Receptor-modified Effector T-cell Populations for Leukemia Cell Therapy. Pizzitola I, Agostoni V, Cribioli E, Pule M, Rousseau R, Finney H, Lawson A, Biondi A, Biagi E, Marin V, J Immunother 2011 34 469 479 10.1097/CJI.0b013e31821e763b 21654519
32. Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy. Ramos CA, Dotti G, Expert Opin Biol Ther 2011 11 855 873 10.1517/14712598.2011.573476 21463133
33. Genetically Modified Donor Leukocyte Transfusion and Graft-Versus- Leukemia Effect After Allogeneic Stem Cell Transplantation. Borchers S, Provasi E, Silvani A, Radrizzani M, Benati C, Dammann E, Krons A, Kontsendorn J, Schmidtke J, Kuehnau W, von Neuhoff N, Stadler M, Ciceri F, Bonini C, Ganser A, Hertenstein B, Weissinger EM, Hum Gene Ther 2011
34. Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. Hoyos V, Savoldo B, Quintarelli C, Mahendravada A, Zhang M, Vera J, Heslop HE, Rooney CM, Brenner MK, Dotti G, Leukemia 2010 24 1160 1170 10.1038/leu.2010.75 20428207
35. An improved bicistronic CD20/tCD34 vector for efficient purification and in vivo depletion of gene-modified T cells for adoptive immunotherapy. Vogler I, Newrzela S, Hartmann S, Schneider N, von Laer D, Koehl U, Grez M, Mol Ther 2010 18 1330 1338 10.1038/mt.2010.83 20461062
36. Engineered human tmpk/AZT as a novel enzyme/prodrug axis for suicide gene therapy. Sato T, Neschadim A, Konrad M, Fowler DH, Lavie A, Medin JA, Mol Ther 2007 15 962 970 10.1038/mt.sj.6300122 17375075 (Pubitemid 46621655)
37. Safer CARS. Heslop HE, Mol Ther 2010 18 661 662 10.1038/mt.2010.42 20357776
38. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA, Mol Ther 2010 18 843 851 10.1038/mt.2010.24 20179677
39. Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial. Brentjens R, Yeh R, Bernal Y, Riviere I, Sadelain M, Mol Ther 2010 18 666 668 10.1038/mt.2010.31 20357779
40. Considerations for the clinical application of chimeric antigen receptor T cells: observations from a recombinant DNA Advisory Committee Symposium held June 15, 2010. Ertl HC, Zaia J, Rosenberg SA, June CH, Dotti G, Kahn J, Cooper LJ, Corrigan-Curay J, Strome SE, Cancer Res 2011 71 3175 3181 10.1158/0008-5472.CAN-10-4035 21531763